Overview
- CDC surveillance and multiple news outlets report roughly 3,400 to 3,544 clinical C. auris detections in about 27–28 states, with the CDC count listed as 3,544 as of Aug. 1.
- The fungus is often resistant to multiple antifungal classes, echinocandins are the main current therapy, and some isolates have shown resistance to all major drug classes including rare pan‑resistant strains.
- UCSF researchers published in Science that, in mice, C. auris binds hair follicles and remodels its cell wall to expose chitin, which triggers interferon‑gamma and suppresses IL‑17–driven antifungal defenses, allowing persistence.
- Because C. auris can colonize skin without symptoms and survive for weeks on surfaces and equipment, it spreads readily in hospitals and long‑term care facilities and forces more screening, isolation, and disinfection work.
- The new mechanism points to possible prevention strategies such as shifting immune signaling toward IL‑17 or blocking chitin but these approaches are experimental and will need human validation before they change infection‑control practice.